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Abstract
Background: Metastatic, chemotherapy-resistant melanoma is an intractable cancer with a very
poor prognosis. As to immunotherapy targeting metastatic melanoma, HLA-A2+ patients were
mainly enrolled in the study in Western countries. However, HLA-A24+ melanoma patients-
oriented immunotherapy has not been fully investigated. In the present study, we investigated the
effect of dendritic cell (DC)-based immunotherapy on metastatic melanoma patients with HLA-A2
or A24 genotype.
Methods: Nine cases of metastatic melanoma were enrolled into a phase I study of monocyte-
derived dendritic cell (DC)-based immunotherapy. HLA-genotype analysis revealed 4 cases of HLA-
A*0201, 1 of A*0206 and 4 of A*2402. Enriched monocytes were obtained using OptiPrep™ from
leukapheresis products, and then incubated with GM-CSF and IL-4 in a closed serum-free system.
After pulsing with a cocktail of 5 melanoma-associated synthetic peptides (gp100, tyrosinase,
MAGE-2, MAGE-3 and MART-1 or MAGE-1) restricted to HLA-A2 or A24 and KLH, cells were
cryopreserved until used. Finally, thawed DCs were washed and injected subcutaneously (s.c.) into
the inguinal region in a dose-escalation manner.
Results: The mean percentage of DCs rated as lin-HLA-DR+ in melanoma patients was 46.4 ± 15.6
%. Most of DCs expressed high level of co-stimulatory molecules and type1 phenotype
(CD11c+HLA-DR+), while a moderate number of mature DCs with CD83 and CCR7 positive were
contained in DC products. DC injections were well tolerated except for transient liver dysfunction
(elevation of transaminases, Grade I-II). All 6 evaluable cases except for early PD showed positive
immunological responses to more than 2 melanoma peptides in an ELISPOT assay. Two
representative responders demonstrated strong HLA-class I protein expression in the tumor and
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very high scores of ELISPOT that might correlate to the regression of metastatic tumors. Clinical
response through DC injections was as follows : 1CR, 1 PR, 1SD and 6 PD. All 59 DC injections in
the phase I study were tolerable in terms of safety, however, the maximal tolerable dose of DCs
was not determined.
Conclusions: These results suggested that peptide cocktail-treated DC-based immunotherapy
had the potential for utilizing as one of therapeutic tools against metastatic melanoma in Japan.
Background
Despite many attempts in the last few years to target can-
cer-specific antigens, a breakthrough in terms of clinical
response has yet to be achieved mainly because of a scar-
city of effective genuine cancer antigens, immunological
evasion, or an immunosuppressive state.
Melanoma-associated antigens are categorized as class I
human leukocyte antigen (HLA)-restricted cancer/testis
antigens [1] which are considered to be tolerable to the
immune system because they are also expressed in normal
tissues. However, malignant melanoma is the most well
known cancer in which multiple tumor-specific antigens
have been defined and utilized in vaccination strategies as
peptide vaccines or peptide-pulsed DC vaccines [2-9].
From a clinical point of view, several vaccination strate-
gies for stage IV melanoma using a combination of several
(more than 3) peptides with a restriction to HLA-A2 have
been reported to date [10,11]. However, little immuno-
therapeutic study regarding HLA-A24-restricted multiple
peptides has been conducted because HLA-A24 is not a
common allele in Caucasians. Several studies have dem-
onstrated the identification of many HLA-A24-restricted
CTL epitopes from various cancer-related antigens includ-
ing p53, CEA, telomerase, tyrosinase, MAGE proteins etc.
[12-18]. When it comes to melanoma, our group demon-
strated the feasibility of using a combination of 5
melanoma-associated peptides with restriction of HLA-
A24 (peptide cocktail) as a specific cancer vaccine in an
immunotherapeutical trial (Akiyama et al, Anticancer
Res., 2004). Based on basic research results, a phase I clin-
ical trial of HLA-A2 or A24-restricted melanoma peptide
cocktail-pulsed dendritic cell-based immunotherapy has
been performed. Here we describe the safety and efficacy
of DC-based immunotherapy against metastatic
melanoma.
Materials and methods
Patient characteristics and eligibility criteria
Nine patients with metastatic melanoma were enrolled in
a phase I clinical trial of a peptide cocktail-pulsed DC-
based vaccine approved by the Institutional Review Board
(No. 12–93 and 12–94) of the National Cancer Center,
Tokyo. All patients gave written informed consent. All
patients had received prior surgery, chemotherapy and
radiation (Table 1). Three subjects had metastatic lesions
in the brain and been given radiation to control them.
Inclusion criteria were: i) biopsy-proven stage IV meta-
static melanoma, ii) age ≥ 18 years, iii) performance status
≤ 2, iv) HLA-A2 or A24 phenotype and v) measurable tar-
get lesions. Exclusion criteria were : i) prior therapy < 4
weeks before trial entry, ii) untreated CNS lesion, iii) preg-
nancy, iv) autoimmune disease, and v) concurrent corti-
costeroid/immunosuppressive therapy. All the patients,
who gave written informed consent, received subcutane-
ously (s.c) 3 DC vaccines at the inguinal region weekly
and toxicity was checked. DCs were injected in dose-esca-
lation design at a dose level per cohort of 1.0, 2,0 and 5.0
× 107/body/shot (Table 1). The injected DC number was
calculated from the percentage of Lin-HLA-DR+ gated pop-
ulations in a FACS analysis.
Table 1: Phase I study of DC-based therapy against melanoma
Patient No. Age Sex Previous therapy Measurable lesions DC injection (times) Side effect DTH Response
peptide KLH
1 41 F ST, CT, RT, IFNβ lung, LN 1 × 107(10) Hepatic (II) - ++ PR
2 75 M ST, CT, IFNβ LN 1 × 107(10) - + + SD
3 49 F ST, CT, IFNβ, RT lung, liver 1 × 107(3) - - - (PD)*
4 49 M ST, CT lung, liver 2 × 107(6) - - - PD
5 50 M ST, CT, IFNβ lung, liver, LN 2 × 107(6) Hepatic (I) - - PD
6 69 M ST, CT, IFNβ LN 2 × 107(10) - + + CR
7 61 M ST, CT, RT liver, LN 5 × 107(8) Hepatic (I) + ++ PD
8 64 F ST, CT, RT lung 5 × 107(3) Fever (I) - - (PD)
9 66 F ST, CT, lung, LN 5 × 107(3) - - - (PD)
* The (PD) patients represent those who received fewer than 4 DC injections because of an early progression of the disease.Journal of Translational Medicine 2005, 3:4 http://www.translational-medicine.com/content/3/1/4
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Preparation of DCs and peptides
Leukapheresis products from 7 L of processed blood were
washed and centrifuged using density-adjusted OptiPrep™
(Axis-Shield PoC, Oslo, Norway), then the monocyte
layer at the top was retrieved. Cells were transferred to an
X-fold culture bag (Nexell, Irvine, CA) and cultured in the
presence of GM-CSF at 50 ng/ml (CellGenix, Freiburg,
Germany) and IL-4 at 50 ng/ml (CellGenix) in X-VIVO15
serum-free medium (Biowhittaker, Walkersville, MD).
After 7 days, harvested cells were pulsed with a cocktail of
5 melanoma-specific synthetic peptides (25 µg/ml each)
restricted to HLA A2 or A24 and KLH (25 µg/ml, Intracell,
Frederick, MD). DC-enriched cells were washed and cryo-
preserved in Cryocyte bags (Baxter Healthcare Co., Deer-
field, IL) until used. The purity of CD14+  cells was
evaluated with a flow cytometer (FACSCalibur, Becton-
Dickinson Co., CA) before and after OptiPrep™ separa-
tion. The percentage of DCs was rated as the lin-HLA-DR+
population (lineage antibodies including CD3, CD14,
CD16, CD19, CD20, CD56 ; Becton-Dickinson Co.). The
additional DC-related markers were determined on gated
lin-HLA-DR+ cells. The following peptides restricted to
HLA-A2 or A24 were synthesized according to GMP stand-
ards by Multiple Peptide Systems, CA. HLA-A2: MART-
127–35  (AAGIGILTV), gp100209–217  (IMDQVPFSV),
tyrosinase368–376  (YMDGTMSQV), MAGE-2157–166
(YLQLVFGIEV), MAGE-3271–279  (FLWGPRALV) ; HLA-
A24: gp100152–160  (VWKTWGQYW), tyrosinase206–214
(AFLPWHRLF), MAGE-1135–143  (NYKHCFPEI), MAGE-
2156–164 (EYLQLVFGI), MAGE-3195–203 (IMPKAGLLI).
Characterization of tumor specimens before DC vaccines
Skin metastatic lesions were obtained from patients who
gave written informed consent. The expression of
melanoma tumor antigens was investigated using RT-PCR
as described previously [19]. HLA protein expression was
also evaluated using an immunohistochemical (IHC)
analysis with anti-HLA-A2 or A24 monoclonal antibody
(One Lambda Inc., Canoga Park, CA). A phenotypical
analysis of lymphocytes infiltrating the tumor site was
also performed using IHC.
Clinical and immunological monitoring
Adverse effects were evaluated according to the NCI Com-
mon toxicity criteria after 3 DC injections. Standard con-
ventional definitions of major (complete or partial)
objective responses were used. Stable disease (SD) was
defined as less than a 25% change in size with no new
lesions lasting at least 4 weeks. Clinical response was rated
as maximal through the DC vaccinations. The patients
received up to 10 injections on the condition that at least
one measurable lesion showed more than stable disease
(SD) response and/or an ELISPOT assay performed after 4
injections indicated a positive response for more than 1
melanoma-associated peptides. PBMC samples were har-
vested before and 29, 78, 134 and 190 days after the 1 st
DC injection, and frozen prior to use for immunological
monitoring tests. All patients were followed up for 2 years
after the enrollment into the study.
ELISPOT assay
The ELISPOT assay was performed using in vitro re-stimu-
lations. Briefly, PBMCs were incubated in a 24-well cul-
ture plate at 4 × 106 per ml and divided into non-adherent
and adherent cells. Adherent cells were treated with a pep-
tide cocktail and β2-microglobulin for 2 hrs, and co-cul-
tured with non-adherent cells in the presence of IL-2 at 15
U/ml and IL-7 at 10 ng/ml. On day 7, non-adherent cells
were re-stimulated with peptide-pulsed adherent cells. On
day14, responder cells (1 × 104/well) were incubated with
peptide-pulsed target cells (1 × 105/well; .221A201 cells
for HLA-A2 peptide or TISI cells for HLA-A24 peptide) in
a 96-well culture plate coated with anti-IFN-γ antibody
(MABTECH AB, Nacka, Sweden) overnight. Finally posi-
tive spots stained with anti-IFN-γ antibody were measured
using the KS ELISPOT system (Carl Zeiss AG, Overkochen,
Germany). HLA-A2-restricted Influenza M1 peptide
(GILGFVFTL) or HLA-A24-restricted EBNA3A peptide
(RYSIFFDY) was used as a negative control.
Tetramer staining
PBMCs were re-stimulated twice in vitro and utilized for
tetramers staining. CD8+-enriched T cells were obtained
by the depletion of CD4+ T cells using Dynabeads M-450
CD4 (Dynal, Oslo, Norway) and used for tetramers stain-
ing. The staining was performed according to the method
reported by Kuzushima et al [20]. The PE-labeled tetram-
ers used in the present study were as follows: HLA-A*0201
MART1 (Beckman Coulter Inc., San Diego, CA), HLA-
A*0201 gp100, HLA-A*2402 tyrosinase, HLA-A*2402
MAGE-1, HLA-A*2402 HIV (RYLRDQQLL) and HLA-
A*0201 Influenza M1 tetramers (MBL, Nagoya, Japan).
Intracellular cytokine staining
PBMCs were stimulated with 25 ng/ml of PMA (Sigma)
and 1 µg/ml of ionomycin (Sigma) for 5 hrs in a 96-well
culture plate. Breferdin A (10 µg/ml) was also added to
cultures in the last hour. After the stimulation, cells were
stained with FITC-anti-CD4 MoAb, and subsequently
intracellular staining was performed with fix/permealiza-
tion buffer and PE-labeled anti-IFN-γ or anti-IL-4 MoAb
(Pharmingen, San Diego, CA). Finally, the ratio of Th1
(IFN-γ+) and Th2 (IL-4+) was calculated in PBMC samples
obtained before and after DC vaccination.
DTH reactions
The HLA-A2 or A24 peptide cocktail solution diluted to a
dose of 5 µg/ml (each peptide) and KLH (50 µg/ml) were
injected intradermally on the patient's forearm and theJournal of Translational Medicine 2005, 3:4 http://www.translational-medicine.com/content/3/1/4
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redness and induration at the injection site was measured.
PPD was used as a positive control.
Statistical analysis
Statistical differences were analyzed using Student's
paired two-tailed t-test. Values of p < 0.05 were considered
significant.
Results
DC characterization
The mean percentage of DCs rated as lin-HLA-DR+ in
melanoma patients was 46.4 ± 15.6 %, not different from
that in healthy volunteers (data not shown). The frequen-
cies of the DC-related markers were determined on gated
lin-HLA-DR+cells : HLA-class I 97.5 ± 0.9 %, CD80 87.6 ±
6.9 %, CD86 85.5 ± 7.4 %, CD1a 55.2 ± 24.2 %, CD83
29.9 ± 13.3 %, CCR7 32.4 ± 13.7 %, DC SIGN 78.2 ± 19.3
%, CD11c+HLA-DR+ 90.6 ± 6.0 %, CD123+HLR-DR+ 0.99
± 1.3 %. Most of DCs expressed high level of co-stimula-
tory molecules and type1 phenotype (CD11c+HLA-DR+),
while a moderate number of mature DCs with CD83 and
CCR7 positive were contained in DC products. On the
other hand, the T cell-stimulating activity of DCs investi-
gated in the MLR assay using allogeneic T cells was as
strong as that of DCs obtained from healthy volunteers
(data not shown).
Characterization of tumor specimen
An analysis of melanoma antigen expression by RT-PCR
was performed in 3 cases. The expression of more than 2
antigens in the tumor was verified in all cases. HLA pro-
tein expression was positive in 5 out of 9 cases (Table 2).
Patient 1 who showed a remarkable clinical response
(PR), was representative of HLA protein-positive cases
(Fig. 1). In contrast, in patient 7, HLA-A2 protein expres-
sion in the tumor was lost in the course of treatment.
ELISPOT assay
CTL precursors of more than 2 melanoma peptides were
recognized after DC vaccines in 6 of 9 cases. Two HLA-A2+
cases (patients 5 and 9) showed HLA-A2 peptide-specific
CTL responses before the vaccination. Patients 1 and 6,
which showed remarkable clinical responses, exhibited
many CTL precursors against a HLA-24 restricted peptide-
cocktail (Table 3, Figure 2). Notably, in patient 1, a
remarkable increase in the CTL response to the HLA-A24
peptide cocktail was seen in accordance with the regres-
sion of metastatic tumor of the lung (Fig. 3). On the other
hand, patient 7 also demonstrated a high CTL precursor
frequency, but showed no significant clinical response.
Tetramer staining
After CD4+ T cell depletion, the frequency of CD8+ cells
was more than 85%. The proportion of PE-labeled tyrosi-
nase-HLA-A24 tetramer-positive cells among gated CD8+
cells was 0.34% in patient 1 (Table 2). HIV-A24 tetramer
(negative control)-positive cells were not detected. The
percentage of PE-labeled MART1-HLA-A2 tetramer-posi-
tive cells was 0.64% and 1.48% in patients 2 and 5,
respectively. On the other hand, that of Influenza M1-
HLA-A2 tetramer (negative control)-positive cells was
0.04%.
Th1 and Th2 balance after DC vaccination
In 5 of 6 evaluable cases, the balance of Th1 and Th2
shifted more to Th1 after 4 DC injections compared with
prior to vaccination. (Table 2). The amplitude of the shift
seemed to be larger in clinical responders (patients 1, 2, 6)
than non-responders (patients 4, 5, 7) (% of ratio
increase; 264 ± 86 vs. 114 ± 35).
DTH
Three of 6 evaluable cases showed positive DTH to a pep-
tide-cocktail after DC injections (Table 1). On the other
hand, 4 of 6 cases developed a DTH response to KLH pro-
Table 2: Immunological monitoring in melanoma patients
Patient No. HLA Tumor antigen, HLA expression ELISPOT Tetramer Th1/Th2 balance
1 A*2402 3/5(Tyr,M1,M2), A24(+) 3/5(Tyr,M1,M2) Tyrosinase (0.34%) 5.19 (1.45)a
2 A*0201 A2(+) 2/5(MART1,gp100) MART1 (0.64%) 3.68 (1.49)
3 A*2402 A24(-) N. Db N. D. -
4 A*0206 A2(-) 2/5(MART1, M2) - 3.05 (2.57)
5 A*0201 A2(-) 2/5(MART1, M2) MART1 (1.48%) 2.83 (3.68)
6 A*2402 2/5(M2,M3), A24(+) 2/5(M2, M3) - 3.76 (2.00)
7 A*0201 4/5(MART1,Tyr,gp100,M2), A2(+) 2/5(gp100, M2) - 2.64 (1.79)
8 A*2402 A24(-) N. D. N. D. -
9 A*0201 A2(+) 1/5(gp100)c N. D. N. D.
aThe value in the parenthesis shows Th1/Th2 ratio prior to DC vaccination. bN. D. ; not done.
cThe value shows the one obtained prior to DC vaccines.Journal of Translational Medicine 2005, 3:4 http://www.translational-medicine.com/content/3/1/4
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tein. There were stronger reactions to KLH in patients 1
and 7.
Adverse effects of DC vaccine
Safety was assessed after 3 DC injections in all 9 cases.
Three of 9 patients developed mild hepatic dysfunction
(grade I-II), however it was only transient and disap-
peared in spite of the continuance of DC injections. Rheu-
matoid factor and anti-nuclear antibody were negative
before the injection, but increased to 1:160 and 1:40,
respectively after the injections finished in patient 1. No
clinical symptoms of autoimmune disease were found in
patient 1 (Table 1).
Clinical response
Clinical response was rated as maximal through the DC
vaccinations. In 6 evaluable cases except for 3 cases of
early PD cases due to a rapid progression of the disease,
1CR (patient 6), 1PR (patient 1), 1SD and 3 PD were
obtained (Table 1). Large metastatic lesions in the lung
and hilar nodes in patient 1 dramatically decreased in size
after 4 DC injections, and almost disappeared after treat-
ment finished (Fig. 3). Moderate sized cervical metastatic
lesions in patient 6 finally started to decrease after 8 DC
injections and disappeared surprisingly rapidly after the
finish of DC therapy. In contrast, patient 7 who exhibited
good immunological responses in the ELISPOT assay and
Immunohistochemical analysis of metastatic tumor tissue from responder patient 1 and non-responder patient 7 Figure 1
Immunohistochemical analysis of metastatic tumor tissue from responder patient 1 and non-responder patient 7. A; H-E stain 
and B; anti-HLA-A24 MoAb from patient 1. C; anti-HLA-A2 MoAb before DC vaccination and D; anti-HLA-A2 MoAb after 4 
DC injections from patient 7. Magnification × 200.
A B
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DTH, showed no shrinkage of the tumor, resulting in ces-
sation after 6 DC injections.
Characterization of infiltrated lymphocytes in the tumor
IHC analysis of infiltrated lymphocytes in the tumor after
DC vaccines was performed only in patient 1 and 7. The
obvious infiltration of a larger number of CD4+ or CD8+ T
cells and a small number of CD20+ B cells were shown in
patient 1 (Fig. 4). In contrast, no significant cell infiltra-
tion was seen in patient 7 who did not develop any thera-
peutical effect on the tumor (data not shown).
Discussion
Clinical trials of specific immunotherapy against meta-
static melanoma using peptide-pulsed Mo-derived DCs
have been performed in mainly Western countries, and
some fruitful results were obtained [7,10,11]. In those
cases, most of the patients belonged to the HLA-A*0201
type. In the present study, we investigated the effect of
peptide-pulsed DCs on 4 cases of HLA-A*2402+ meta-
static melanoma patients besides 4 cases of HLA-A*0201+
patients in a clinical phase I trial. This is the first report to
demonstrate that peptide-pulsed DCs were effective in
some HLA-A24+ melanoma patents in Japan. It is well
known that HLA-A*2402 is a common genotype and
around 60% positive in Asians. There was one case of
HLA-A*0206 patient among 5 HLA-A2+ patients (Table
2). Sidney et al. [21] demonstrated that over 70% of the
peptides that bound A0201 with high affinity were found
to bind at least two other supertype molecules like
A*0202, A*0203 or A*0206. Taking it into considera-
tions, the HLA-A*0206 patient was finally enrolled into
the study. With regard to other HLA-A24+ solid cancers,
stomach, colon and bladder cancers have been treated
with peptide (MAGE-3)-pulsed DC vaccines, and showed
a limited response [22-24]. Considering that melanoma is
highly immunogenic and probably a good model for
tumor-specific immunotherapy despite being an unusual
tumor in Asian countries, it deserves a phase I study using
peptide-pulsed DCs.
In our study, peptide cocktails combining 5 peptides for
each HLA type (HLA-A2 or A24) were prepared and used
for DC pulsing. Our clinical study revealed positive ELIS-
POT responses against more than 2 peptides in all 6 eval-
uable cases. In previous reports, clinical DC therapy using
more than 3 melanoma peptides demonstrated the induc-
tion of a specific CTL response against multiple
melanoma peptides [10,11]. However,, there is still some
controversy over the efficacy of multiple epitope-based
vaccinations and Smith et al. [25] demonstrated that,
although polyepitope vaccines are an effective way of
priming polyvalent CTLs, continual stimulation with pol-
yepitope vaccines might restrict CTL induction as a result
of immunodominance. The results of our study are
thought to answer that question, but testing of the peptide
cocktail vaccine in more patients will be needed.
To refine the quality and protocol of the tumor-specific
immunotherapy for clinical trials, the prediction of clini-
cal response in an individual is important [26] and should
be discussed. In our study, the correlation between immu-
nological parameters and clinical response was investi-
gated in a limited number of cases.
First of all, as to HLA expression in the tumor, patients 1,
2, 6 and 7 were positive, and patients 4 and 5 were
negative. HLA-negative cases showed a progression of the
tumor. Even in positive cases, patient 7 turned negative in
the course of DC therapy, showing tumor progression.
Table 3: Peptide cocktail-specific CTL precursor frequency during DC vaccination
Spot No./CD8+ T cell (%)a
Patient No. DC injection 
(times)
before day29 day78 day134 day190
11  ×  1 0 7(10) 1.19/0.45 6.96/0.06 8.82/0.63 8.81/0.08 5.4/0.08
21  ×  1 0 7(10) 0.07/0.05 0.07/0.2 0.02/0 0.02/0 0.29/0.03
31  ×  1 0 7(3) N.D.b N.A.c N.A. N.A. N.A.
42  ×  1 0 7(6) 0.39/0.53 1.29/0.03 1.12/0 N.A. N.A.
52  ×  1 0 7(6) 1.74/0.05 0.51/0.2 1.25/0.04 N.A N.A.
62  ×  1 0 7(10) 0.21/0.27 0.31/0.28 1.18/0.24 7.80/0.19 9.82/0.30
75  ×  1 0 7(8) 0.62/0.20 6.52/0.1 7.33/0.11 N.A. N.A.
85  ×  1 0 7(3) N.D. N.A. N.A. N.A. N.A.
95  ×  1 0 7(3) 3.09/1.24 N.D. N.A. N.A. N.A.
The percentages represent IFN-γ-positive spot No. divided by total CD8+ cell No. from 1 × 104 PBMCs. aEach value represents the percentage with 
peptide cocktail/without peptide cocktail. bN.D. ; not done, cN.A. ; sample not available.Journal of Translational Medicine 2005, 3:4 http://www.translational-medicine.com/content/3/1/4
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Loss of HLA expression in melanoma is reported to be a
complex phenomenon associated with melanoma
antigen loss [27], β2-microglobulin gene mutation [28] or
loss of heterozygosity (LOH) in chromosome 6 and may
lead to tumor progression and metastasis. As to patient 7,
considering that the melanoma antigen expression was
maintained, the functional expression of β2-microglobu-
lin should be investigated. All the other HLA-positive
cases showed CR, PR and SD, respectively. There was a
tendency for HLA expression to be associated with tumor
response, and some researchers reported a positive corre-
lation of HLA-expression to tumor response in immuno-
therapy against melanoma. However, despite the positive
correlation of HLA-expression in the tumor with anti-
tumor response, Nestle et al. demonstrated that HLA-
expression in the tumor did not correlate to survival in
melanoma patients [29].
Second, the amplitude of the CTL response in the ELIS-
POT assay seems to be another key factor predicting anti-
tumor response. Patients 1, 6 and 7 showed large
responses to peptide cocktail in ELISPOT, and patients 2,
4 and 5 showed small responses. The former exhibited a
remarkable regression of tumor except patient 7. On the
other hand, the latter showed a poor response. There was
a likely tendency that the amplitude of the CTL response
was associated with tumor regression. Also, it was difficult
to predict when immunological responses like CTL induc-
CTL responses in the course of DC injections in 6 evaluable cases Figure 2
CTL responses in the course of DC injections in 6 evaluable cases. Patients 1, 2 and 6 were responders and patients 4, 5 and 7 
were non-responders. Responders (cases 1,6) showed remarkable CTL expansion in PBLs compared with before DC vaccina-
tion. In contrast, non-responders (patients 4,5) showed no significant CTL responses except in patient 7.
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tion start to be activated in vivo during DC vaccination,
and this question needs to be answered. In the present
study, because of a limited number of patients given DC
vaccines, the tendency that HLA-class I protein expression
in the tumor and the amplitude of ELISPOT responses are
seemingly associated with tumor regression is not
convincing.
Finally, in order to improve tumor response in the present
study, there are still some issues regarding clinical DC
preparation. First of all, the purity of CD14+ cells after
Opti-prep separation is still low and may not be reproduc-
ible. Therefore, other clinical grade-monocyte separation
methods using an elutriator or negative selection with
CD2 and CD19 MoAbs [30] should be tried. Second, con-
sidering that the amplitude of the CTL response was asso-
ciated with tumor regression, and that even a remarkable
increase of CTL frequency inevitably diminished in spite
of the repetition of DC vaccinations, it seems to be crucial
to maintain increased CTL frequency in blood leading to
TIL in the tumor and expand more than enough to
develop a substantial number of memory CD8+ CTL in
lymph nodes. Such a novel method will be needed to
develop an effective cancer vaccine.
Conclusions
In the present study, we investigated the effect of dendritic
cell (DC)-based immunotherapy on metastatic
melanoma patients with HLA-A2 or A24 genotype. Nine
cases of metastatic melanoma were enrolled into a phase
I study using HLA-A2 or A24-restricted peptide cocktail-
pulsed DCs. All 6 evaluable cases showed positive
immunological responses to more than 2 melanoma pep-
tides in an ELISPOT assay. Clinical response through DC
injections was as follows : 1CR, 1 PR, 1SD and 6 PD. All
59 DC injections in the phase I study were safely adminis-
tered to patients. These results suggested that peptide
cocktail-treated DC-based immunotherapy had the
potential for utilizing as one of therapeutic tools against
HLA-A2 or A24+ metastatic melanoma.
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